Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$226K Buy
1,761
+30
+2% +$3.51K 0.07% 120
2026
Q1
$208K Sell
1,731
-261
-13% -$30.1K 0.07% 118
2025
Q4
$210K Buy
+1,992
New +$187K 0.07% 115
2025
Q1
Sell
-2,339
Closed -$233K 104
2024
Q4
$233K Sell
2,339
-206
-8% -$21.2K 0.1% 97
2024
Q3
$289K Sell
2,545
-278
-10% -$33K 0.13% 91
2024
Q2
$349K Sell
2,823
-17,276
-86% -$2.23M 0.18% 78
2024
Q1
$2.65M Sell
20,099
-12,253
-38% -$1.51M 1.44% 21
2023
Q4
$1.77M Buy
32,352
+16,324
+102% +$1.69M 1.02% 44
2023
Q3
$1.65M Buy
16,028
+1,174
+8% +$127K 1.01% 46
2023
Q2
$1.71M Buy
+14,854
New +$1.69M 1.07% 41

Other funds holding MRK

Slagle Financial's MRK Position: Q2 2026 in Review

Slagle Financial increased its Merck (MRK) stake by 1.7% in Q2 2026, buying an estimated $3.51K and bringing the position to 1,761 shares worth $226K. The position accounts for 0.07% of the portfolio, ranked #120.

Slagle Financial first reported a position in MRK in Q2 2023 and has held it in 10 quarters since. The position peaked at $2.65M in Q1 2024. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Slagle Financial held 1,761 shares of Merck worth $226K as of Q2 2026.
  • Slagle Financial bought 30 Merck shares in Q2 2026, an estimated $3.51K.
  • Merck made up 0.07% of Slagle Financial's portfolio in Q2 2026, its #120 holding.
  • Slagle Financial first reported a position in Merck in Q2 2023 and has held it in 10 quarters since.
  • Slagle Financial's Merck position peaked at $2.65M in Q1 2024.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Slagle Financial's 13F filing for Q2 2026, filed 29 Jul 2026.